Despite the proven efficacy and safety of medications for ADHD, abuse is a growing concern.
Seven common questions about addiction clinicians regularly hear—as well as the answers.
Recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously thought.
A novel compound holds promise for addressing cognitive deficits in schizophrenia.
An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.
No better time than the summer to digest and reflect on the richness of our field and how we can implement advances in our own work.
A review of systemic medications for dermatologic diseases describes a wide range of adverse events, which range from mild and reversible to permanent and potentially fatal.
The impetus to consider inflammation as potentially relevant to the pathoetiology of domain-based psychopathology (eg, anhedonia) and/or mental disorders, is
provided by a confluence of factors discussed here.
The studies reviewed in this article provide a new model for clinical practice—one where the treatment of depressed patients is not governed by trial and error, but rather where patients can access new interventions sooner.
A drug once seen as a widespread danger to society is now experiencing renewed interest as a treatment for medical conditions, including a number of mental health conditions. This brief review explores 5 key issues clinicians can consider when encountering the therapeutic cannabis user.